UROP Project

3D Bioprinting: technology-driven research in the field of tissue engineering

Contact

Name

Daniel Holder

Program Director UROP

Telephone

workPhone
+49 241 80-90695

E-Mail

Key Info

Basic Information

Project Offer-Number:
590
Category:
UROP International
Field:
Biomedical Engineering, Mechanical Engineering, Electrical Engineering
Faculty:
10
Organisation unit:
Dental Materials and Biomaterials Research (Prof. Fischer, www.biomaterials-research.de)
Language Skills:
English
Computer Skills:
CAD (optional), Programming (optional), CFD Simulation (optional)
Others:
-A medical certificate that confirms a full hepatitis B immunization is required to work in our S1 bioprinting lab.-A medical certificate that confirms a full hepatitis B immunization is required to work in our S1 bioprinting lab. -We prefer students who can stay until the end of August.
Professor:
Professor Dr.-Ing. Horst Fischer

Bioprinting technology enables to build up constructs made of hydrogels in 3D loaded by living human cells. Among the different bioprinting techniques in particular drop-on-demand printing, microextrusion, and acoustic bioprinting as well as combinations thereof are focused in our lab. Subsequently to the printing procedure the embedded cells mature towards functional 3D tissues in a cultivation process. Such bioprinted and matured tissues can be used as 3D in vitro models to study fundamental biological mechanisms or as drug screening platforms and - to some extent - for in vivo replacement of tissues. www.biomaterials-research.de

Task

-Testing and improving the bioprinting devices in our lab -Synthesis and characterization of novel hydrogels -Biofabrication of cell loaded hydrogel constructs -Analysis of the 3D printed structures (mechanically and biologically) -Development of novel biofabrication concepts

Requirements

Knowledge and strong interest in one of the following fields: -Tissue Engineering -Biomedical Engineering -Mechanical Engineering -Electrical Engineering Students will work in the lab where patient derived material is regularly used. For this reason, a confirmation that the antibody titer against hepatitis B is higher than 100 IU/L is required.